Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2004

01-10-2004 | Original Article

Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET

Authors: D. Otto, A. R. Boerner, M. Hofmann, T. Brunkhorst, G. J. Meyer, T. Petrich, G. F. Scheumann, W. H. Knapp

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2004

Login to get access

Abstract

Purpose

Previous studies have shown high sensitivity of positron emission tomography (PET) with 11C-methionine in the pre-operative localisation of parathyroid adenoma and hyperplasia. Nonetheless, in secondary and tertiary hyperparathyroidism (HPT) and in patients with recurrent disease, pre-operative localisation of adenomatous (PTA) or hyperplastic tissue is still a problem with all available methods. The aim of this study was to define the optimal imaging protocol and to compare the diagnostic value of 11C-methionine PET and 99mTc-methoxyisobutylisonitrile (MIBI) single-photon emission computed tomography (SPECT): in particular, we wished to define the benefit of 11C-methionine in those patients with inconclusive or negative conventional imaging.

Methods

Thirty highly pre-selected patients with HPT were enrolled. Sixteen patients had primary HPT, 12 patients had secondary HPT, and two patients had recurrences of parathyroid carcinomas. All patients had ultrasound of the neck, dual-phase scintigraphy with 99mTc-MIBI and PET with 11C-methionine. SUVparathyroid/SUVcervical soft tissue (target-to-background) and SUVparathyroid tissue/SUVthyroid tissue (target-to-non-target) ratios were calculated. After surgery, histology of specimens was obtained in all patients but one.

Results

In 12 patients with secondary or tertiary HPT, 36 hyperplastic parathyroid glands were histologically verified. Twenty-five of 36 lesions (69%) were detected with 11C-methionine PET and 17 (47%) with 99mTc-MIBI scintigraphy. PET studies were positive in 17/18 (94%) cases in which HPT was related to adenomas or carcinomas. 99mTc-MIBI scintigraphy/SPECT yielded pathological lesions in 9/18 cases (50%). All eight atypical localisations of parathyroid glands were detected with PET but only six of the eight were detected with 99mTc-MIBI scintigraphy/SPECT. In 10/11 patients with recurrent HPT and non-diagnostic scintigraphy/SPECT, hyperfunctional parathyroid tissue was identified with 11C-methionine PET. The highest SUVparathyroid/SUVcervical soft tissue ratio was found 10 min, and the highest SUVparathyroid tissue/SUVthyroid tissue ratio 40 min post injection. In three patients clear delineation of hyperfunctional tissue was only achieved after 40 min post injection.

Conclusion

11C-methionine PET is a clinically useful method in highly pre-selected patients with recurrent primary HPT as well as in secondary and tertiary HPT if ultrasound and 99mTc-MIBI SPECT are inconclusive or negative. PET imaging of atypical PTA localisations is more accurate than conventional scintigraphy. In order to achieve optimal contrast of parathyroid glands versus thyroid tissue and adjacent soft tissue, imaging at both 10 min and 40 min is recommended.
Literature
1.
Alexander HR Jr, Chen CC, Shawker T, Choyke P, Chan TJ, Chang R, Marx SJ. Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002;17(Suppl 2):N133–40.PubMed
2.
Giordano A, Rubello D, Casara D. New trends in parathyroid scintigraphy. Eur J Nucl Med 2001;28:1409–20.CrossRefPubMed
3.
Wakamatsu H, Noguchi S, Yamashita H, Yamashita H, Tamura S, Jinnouchi S, et al. Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with 99mTc-MIBI, 201Tl, MRI and US. Eur J Nucl Med 2001;28:1817–27CrossRefPubMed
4.
Dietlein M, Knapp WH, Lauterbach KW, Schicha H. Economic evaluation studies in nuclear medicine: the need for standardization [review]. Eur J Nucl Med 1999;26:663–80.CrossRefPubMed
5.
Nilsson B, Fjalling M, Klingenstierna H, Molne J, Jansson S, Tisell LE. Effects of preoperative parathyroid localisation studies on the cost of operations for persistent hyperparathyroidism. Eur J Surg 2001;167:587–91.CrossRefPubMed
6.
Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 2002;236:543–51.CrossRefPubMed
7.
Casara D, Rubello D, Pelizzo MR, Shapiro B. Clinical role of 99mTcO4/MIBI scan, ultrasound and intra-operative gamma probe in the performance of unilateral and minimally invasive surgery in primary hyperparathyroidism. Eur J Nucl Med 2001;28:1351–9.CrossRefPubMed
8.
Hallfeldt KK, Trupka A, Gallwas J, Horn K. Minimally invasive video-assisted parathyroidectomy. Surg Endosc 2001;15:409–12.CrossRefPubMed
9.
Lorenz K, Miccoli P, Monchik JM, Duren M, Dralle H. Minimally invasive video-assisted parathyroidectomy: multiinstitutional study. World J Surg 2001;25:704–7.CrossRefPubMed
10.
Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol 2002;57:241–9.CrossRef
11.
Krausz Y, Lebensart PD, Klein M, Weininger J, Blachar A, Chisin R, Shiloni E. Preoperative localization of parathyroid adenoma in patients with concomitant thyroid nodular disease. World J Surg 2000;24:1573–8.CrossRefPubMed
12.
Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Technetium 99m-MIBI-SPECT: a highly sensitive diagnostic tool for localization of parathyroid adenomas. Surgery 2000;128:29–35.CrossRefPubMed
13.
Pattou F, Huglo D, Proye C. Radionuclide scanning in parathyroid diseases. Br J Surg 1998;85:1605–16.CrossRefPubMed
14.
Rink T, Schroth HJ, Holle LH, Garth H. Limited sensitivity of parathyroid imaging with 99mTc-sestamibi/123I subtraction in an endemic goiter area. J Nucl Med 2002;43:1175–80.PubMed
15.
Scheiner JD, Dupuy DE, Monchik JM, Noto RB, Cronan JJ. Pre-operative localization of parathyroid adenomas: a comparison of power and colour Doppler ultrasonography with nuclear medicine scintigraphy. Clin Radiol 2001;56:984–8.CrossRefPubMed
16.
Takebayashi S, Hidai H, Chiba T, Takagi Y, Nagatani Y, Matsubara S. Hyperfunctional parathyroid glands with 99mTc-MIBI scan: semiquantitative analysis correlated with histologic findings. J Nucl Med 1999;40:1792–7.PubMed
17.
Cook GJ, Wong JC, Smellie WJ, Young AE, Maisey MN, Fogelman I. (11C)Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998;139:195–7.PubMed
18.
Hellman P, Ahlstrom H, Bergstrom M, Sundin A, Langstrom B, Westerberg G, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 1994;116:974–81.PubMed
19.
Lawson MA, Targovnik JH, Chen K, Bandy DJ, Goodwin SJ, Mullen LB, et al. Three cases of primary hyperparathyroidism (PHP) with prior failed surgery where culprit lesions were identified by 11C-methionine positron emission tomography (PET) and accurately localized with PET–MRI coregistration. Clin Positron Imaging 2000;3:31–6.CrossRefPubMed
20.
Melon P, Luxen A, Hamoir E, Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995;22:556–8.PubMed
21.
Neumann DR, Esselstyn CB, MacIntyre WJ, Chen EQ, Go RT, Kohse LM. Parathyroid adenoma localization by PET FDG. J Comput Assist Tomogr 1993;17:976–7.PubMed
22.
Neumann DR, Esselstyn CB Jr, MacIntyre WJ, Chen EQ, Go RT, Licata AA. Regional body FDG-PET in postoperative recurrent hyperparathyroidism. J Comput Assist Tomogr 1997;21:25–8.CrossRefPubMed
23.
Sundin A, Johansson C, Hellman P, Bergstrom M, Ahlstrom H, Jacobson GB, et al. PET and parathyroid l-[carbon-11]methionine accumulation in hyperparathyroidism. J Nucl Med 1996;37:1766–70.PubMed
24.
Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993;189(3):847–50.PubMed
25.
Greenspan BS, Brown ML, Dillehay GL, McBiles M, Sandler MP, Seabold JE, Sisson JC. Procedure guideline for parathyroid scintigraphy. Society of Nuclear Medicine. J Nucl Med 1998;39:1111–4.PubMed
26.
Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Leger A, Lopez J, et al. [99mTc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations. Nephrol Dial Transplant 2000;15:1201–6.CrossRefPubMed
27.
Pons F, Torregrosa JV, Vidal-Sicart S, Sabater L, Fuster D, Fernandez-Cruz L, Herranz R. Preoperative parathyroid gland localization with technetium-99m sestamibi in secondary hyperparathyroidism. Eur J Nucl Med 1997;24:1494–8.CrossRefPubMed
28.
Torregrosa JV, Palomar MR, Pons F, Sabater L, Gilabert R, Llovera J, Fernandez-Cruz L. Has double-phase MIBI scintigraphy usefulness in the diagnosis of hyperparathyroidism? Nephrol Dial Transplant 1998;13:37–40.CrossRef
29.
Habener JF, Rosenblatt M, Potts JT Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 1984;64:985–1053.PubMed
Metadata
Title
Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET
Authors
D. Otto
A. R. Boerner
M. Hofmann
T. Brunkhorst
G. J. Meyer
T. Petrich
G. F. Scheumann
W. H. Knapp
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1610-1

Other articles of this Issue 10/2004

European Journal of Nuclear Medicine and Molecular Imaging 10/2004 Go to the issue

Original Article

Value of 18F-FDG PET in the detection of peritoneal carcinomatosis

Editorial Commentary

From the magic bullet to an effective therapy: the peptide experience

Original Article

Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay

Original Article

99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer

Original Article

Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of β-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis

Original Article

In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937